



"ELPEN PHARMACEUTICAL Co. INC."

95, Marathonos Ave. 19009 Pikermi

Companies Reg. No.: 13231/04/B/86/188

G.E.MI. No.: 264601000

CONSOLIDATED FINANCIAL STATEMENTS

Year 2017

1 January to 31 December 2017

Independent Auditor's Report

To the Shareholders of **ELPEN PHARMACEUTICAL Co. INC.**

Report on the Audit of the Consolidated Financial Statements

Qualified Opinion

We have audited the accompanying consolidated financial statements of ELPEN PHARMACEUTICAL Co. INC. (the Company), which comprise the consolidated balance sheet as at 31 December 2017, and the consolidated statements of income, changes in equity and cash flows for the year then ended, and notes to the financial statements.

In our opinion, except for the effects of the matters (1) and (2) and the possible effects of the matter (3) described in the “Basis for Qualified Opinion” section of our report, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of ELPEN PHARMACEUTICAL Co. INC. and its subsidiary (the Group) as at 31 December 2017, their financial performance and their cash flows for the year then ended in accordance with the requirements of the L. 4308/2014 as in force.

Basis for Qualified Opinion

As a result of our audit arose the following matters:

- 1) In “Other intangible assets” is included also an amount of Euro 10.007.143,32 which concerns the net book amount of the debit difference arising from the Greek Government Bonds swap amounting Euro 12.507.365,73 in order this to be partially and equally transferred to the expenses, over the years 2012-2041, that can be deducted from the taxable income. Because this item, according to the accounting principles provided by the Greek Accounting Standards, does not meet the criteria of recognition as a property asset, the unamortized balance of the account “Other intangible assets” and the Equity are shown increased by amount Euro 10.007.143,32.

- ~~2) In trade receivables are included also receivables overdue as well as doubtful-contested receivables totalling approximately Euro 1.715.000,00, where the calculated impairment of their value amounting Euro 1.255.198,25 falls short of the required by approximately Euro 460.000,00. Non performing the required impairment constitutes deviation from the accounting principles provided by the Greek Accounting Standards and, as a consequence, the value of the trade receivables and the Equity are shown equally in amount increased.~~
- 3) The tax returns of the subsidiary for the years 2016 to 2017 have not been examined by the tax authorities as yet. Therefore, the tax results for these years have not been made final. The companies of the group have not proceeded to estimation of additional taxes and penalties that may be assessed at a future tax audit and has not made relevant provision in respect of this contingent liability. From our audit reasonable assurance has not been obtained in respect of the estimation of the amount of provision that may be required.

We conducted our audit in accordance with International Standards on Auditing (ISAs) as incorporated into the Greek Legislation. Our responsibilities under those standards are further described in the “Auditor’s Responsibilities for the Audit of the separate and consolidated Financial Statements” section of our report. We are independent of the Company and its consolidated subsidiaries throughout our appointment in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code), as incorporated into the Greek Legislation and the ethical requirements that are relevant to the audit of the separate and consolidated financial statements in Greece, and we have fulfilled our other ethical responsibilities in accordance with the requirements of the current legislation and the above-mentioned IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the requirements of the L. 4308/2014 as in force, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs, as incorporated into the Greek Legislation, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs as incorporated into the Greek Legislation, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

Taking into consideration that management is responsible for the preparation of the Board of Directors' Report, according to the provisions of paragraph 5 of article 2 (part B') of L. 4336/2015, we note that:

- a) In our opinion the Board of Directors' Report has been prepared in accordance with the applicable legal requirements of the articles 43a and 107A of cod. L. 2190/1920 and its content corresponds with the accompanying consolidated financial statements for the year ended 31/12/2017.
- b) Based on the knowledge we obtained during our audit of ELPEN PHARMACEUTICAL Co. INC. and its environment, we have not identified any material misstatements in the Board of Directors' Report.

Athens, 3 August 2018

IOANNIS K. KATSINELIS

Certified Public Accountant Auditor
Institute of CPA (SOEL) Reg. No. 13441

ΣΟΛ  **Crowe SOL™**

CERTIFIED PUBLIC ACCOUNTANTS

Associated Certified Public Accountants s.a.
member of Crowe Horwath International
3, Fok. Negri Street - 112 57 Athens, Greece
Institute of CPA (SOEL) Reg. No. 125

CONSOLIDATED BALANCE SHEET AT 31 DECEMBER 2017

ASSETS	31/12/2017	31/12/2016
Non-current assets		
Tangible assets		
Land-Buildings	15.820.961,03	16.145.837,40
Mechanical equipment	4.793.312,00	4.159.318,82
Other equipment	432.942,93	361.299,94
Total	21.047.215,96	20.666.456,16
Intangible assets		
Other intangible assets	10.828.601,96	11.093.324,73
Total	10.828.601,96	11.093.324,73
Payments on account and non-current assets in course of construction	2.729.960,59	2.006.173,85
Financial assets		
Loans and receivables	39.645,35	35.185,35
Held to maturity investments	6.464.997,23	5.193.702,86
Participating interests in subsidiaries, associates and joint ventures	72.790,62	0,00
Total	6.577.433,20	5.228.888,21
Total non-current assets	41.183.211,71	38.994.842,95
Current assets		
Inventories		
Finished and semi-finished products	7.679.067,52	7.635.589,73
Merchandise	2.952.568,80	3.080.361,27
Raw materials and consumables	9.454.675,58	6.420.922,56
Payments on account for inventories	0,00	42.900,75
Total	20.086.311,90	17.179.774,31
Financial assets and payments on account		
Trade receivables	31.792.742,38	32.781.600,12
Accrued income	1.208.556,21	3.478.469,88
Other receivables	2.562.319,61	2.871.664,94
Other financial assets	2.574,00	2.574,00
Prepaid expenses	79.009,14	80.140,54
Trading portfolio	8.191.222,23	569.737,83
Cash and cash equivalents	62.263.846,07	61.165.938,30
Total	106.100.269,64	100.950.125,61
Total current assets	126.186.581,54	118.129.899,92
Total Assets	167.369.793,25	157.124.742,87

ELPEN PHARMACEUTICAL Co. INC.

Consolidated
2017

Financial
6

Statements

-

Year

LIABILITIES	31/12/2017	31/12/2016
Equity		
Paid-up capital		
Capital	46.189.410,00	46.189.410,00
Total	46.189.410,00	46.189.410,00
Reserves and retained earnings		
Statutory reserve	4.734.969,81	4.708.677,73
Tax-free reserves	2.080.059,21	3.735.231,97
Retained earnings	-2.684.216,01	288.683,70
Total	4.130.813,01	8.732.593,40
Total equity	50.320.223,01	54.922.003,40
Provisions		
Provisions for employee benefits	8.381.765,19	8.192.890,83
Other provisions	0,00	0,00
Total	8.381.765,19	8.192.890,83
Liabilities		
Current liabilities		
Trade payables	64.443.667,09	59.693.709,19
Income tax	0,00	822.009,04
Other taxes and duties	1.404.658,90	1.760.372,94
Social security organizations	1.440.965,06	1.315.263,56
Other payables	32.865.569,02	22.835.447,13
Accrued expenses	8.512.944,98	7.583.046,78
Total	108.667.805,05	94.009.848,64
Total liabilities	108.667.805,05	94.009.848,64
Total Equity, Provisions and Liabilities	167.369.793,25	157.124.742,87

STATEMENT OF INCOME by FUNCTION

	31/12/2017	31/12/2016
Turnover (net)	118.567.175,32	125.097.946,76
Cost of sales	-56.069.539,17	-55.030.747,79
Gross profit/(loss)	62.497.636,15	70.067.198,97
Other operating income	256.347,36	380.011,45
	62.753.983,51	70.447.210,42
Administrative expenses	-18.549.350,71	-17.710.264,75
Distribution costs	-38.401.581,50	-38.675.541,03
Research & development costs	-6.736.016,06	-6.957.036,23
Impairment of assets (net amount)	1.271.294,37	504.835,80
Gains & losses on disposal of non-current assets	29.799,98	2.697,27
Income from participating interests and investments	1.262.809,43	637.622,57
Other expenses and losses	-1.886.346,80	-1.553.229,97
Other income and gains	163.383,95	2.436.555,35
Earnings/(loss) before interest and tax (EBIT)	-92.023,83	9.132.849,43
Interest expense and similar charges	-34.941,32	-44.696,30
Profit/(loss) before income tax	-126.965,15	9.088.153,13
Income tax expense	-14.834,49	-864.812,61
Profit/(loss) for the period net of tax	-141.799,64	8.223.340,52

STATEMENT OF CHANGES IN EQUITY

	Capital	Statutory reserve	Tax-free reserves	Retained earnings	Total equity
Balance at 1 January 2016	38.189.410,00	4.480.822,59	3.735.231,97	-8.204.734,86	38.200.729,70
Increase/(decrease) in the period	8.000.000,00			497.933,18	8.497.933,18
Internal transfers					0,00
Distribution to parties					0,00
Profit/(loss) for the period		227.855,14		7.995.485,38	8.223.340,52
Total change in equity for the period	8.000.000,00	227.855,14	0,00	8.493.418,56	16.721.273,70
Balance equity at 31 December 2016	46.189.410,00	4.708.677,73	3.735.231,97	288.683,70	54.922.003,40
Balance at 1 January 2017	46.189.410,00	4.708.677,73	3.735.231,97	288.683,70	54.922.003,40
Increase/(decrease) in the period				-164.365,52	-164.365,52
Internal transfers			-1.655.172,76	1.655.172,76	0,00
Distribution to parties				-4.295.615,23	-4.295.615,23
Profit/(loss) for the period		26.292,08		-168.091,72	-141.799,64
Total change in equity for the period	0,00	26.292,08	-1.655.172,76	-2.972.899,71	-4.601.780,39
Balance equity at 31 December 2017	46.189.410,00	4.734.969,81	2.080.059,21	-2.684.216,01	50.320.223,01

STATEMENT OF CASH FLOWS (Indirect Method) at 31.12.2017

	Consolidated Cash Flows 31/12/2017
<u>Cash flows from operating activities</u>	
Profit before taxes	472.757,44
Plus/Less adjustments for:	
Depreciation and impairment of tangible and intangible assets	2.213.560,04
Provisions	342.049,22
Profit and losses from disposal of assets	-29.786,72
Profit and losses from measurement of assets	-1.252.120,34
Interest expense/income (net amount)	-1.227.868,11
Operating profit before adjustments of working capital	518.591,53
Plus/Less adjustments of working capital to net cash or related to operating activities:	
Decrease/(increase) of inventories	-3.095.610,62
Decrease/(increase) of receivables	4.467.529,86
Increase/(decrease) of payables	14.006.939,43
Less:	0,00
Interest expense/income paid/received	-34.941,32
Income tax paid	-822.009,04
Net cash flows from operating activities (a)	15.040.499,84
<u>Cash flows from investing activities</u>	
Payments (proceeds) for acquisition (sale) of fixed assets	-3.311.634,17
Granted loans (net)	0,00
Interest received	1.262.809,43
Dividends received	0,00
Purchases of securities	-7.598.152,20
Net cash used in investing activities (b)	-9.646.976,94
<u>Cash flows from financing activities</u>	
Proceeds (payments) from increase/(decrease) of capital	0,00
Proceeds/(repayments) from/(of) loans	0,00
Dividends paid	-4.295.615,13
Net cash used in financing activities (c)	-4.295.615,13
Net increase/(decrease) in cash and cash equivalents (a) + (b) + (c)	1.097.907,77
Cash and cash equivalents at beginning of the period	61.165.938,30
Cash and cash equivalents at end of the period	62.263.846,07

Pikermi, 25 July 2018

THE CHAIRMAN OF THE B. OF D.

THE VICE CHAIRMAN OF THE B. OF D.

DIMITRIOS KON. PENTAFRAGKAS
ID. No. AE 562381

THEODOROS ELEFTH. TRYFON
ID No. AH 621121

THE MANAGING DIRECTOR

THE ACCOUNTING MANAGER

KONSTANTINOS DIM. PENTAFRAGKAS
ID. No. AE 024765

ZANIS KON. PAPOURTZIS
E.C.G. Licence No. 0006923/A' Class